Extended-release Adhansia XR has a clinical effect up to 16 hours

By Brian Buntz | July 21, 2021

adhansiaxr Adhansia XR Adlon Therapeutics attention deficit hyperactivity disorder (ADHD) Adhansia XR from Adlon Therapeutics is a long-acting central nervous system stimulant indicated for attention deficit hyperactivity disorder (ADHD) in children aged 6 and older.

Adlon recently announced that in a clinical trial, ADHD patients had a significant improvement in symptoms starting after one hour after taking the drug and up to 16 hours.

Adlon recently won approval for a supplemental New Drug Application to include supplementary clinical data in adult patients with ADHD.

Filed Under: Neurological Disease
Tagged With: Adhansia XR, ADHD, Adlon Therapeutics, attention deficit hyperactivity disorder

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.